INTRACAVERNOUS VASOACTIVE THERAPY OF ERECTILE DYSFUNCTION


Authors: MUDr. Jiří Heráček 1,2;  doc. MUDr. Michael Urban 1,2;  MUDr. Martin Lukeš 1;  Doc. MUDr. Roman Zachoval, Ph.D.;  MUDr. Miroslav Záleský 1 1;  MUDr. Lukáš Bittner 1
Authors‘ workplace: Urologická klinika 3. LF UK a FNKV, Praha 1;  Androgeos - soukromé urologické a andrologické centrum, Praha 2
Published in: Urol List 2006; 4(1): 49-52

Overview

Erectile dysfunction (ED) is, with an incidence rate of 10%, the most common sexual dysfunction in male adult populations. The intracavernous application of vasoactive agents has been used in treating ED for more than 20 years. This method is based on "self-injecting" vasoactive agents into the corpora carvernosa. The dosage is strictly individual and alprostadil is the most frequently used drug. This treatment gives two great advantages - high efficacy and erection without sexual stimulation, and disadvantages - discomfort associated with therapy and above all the risk of prolonged erection. This treatment is safe and adheres to the rules; however, it is necessary to follow up the patient with an urologist.

KEY WORDS:
erectile dysfunction, intracavernous therapy, prostaglandin E1


Sources

1. NIH Consensus Development Panel on Impotence. (NIH Consensus Conference. Impotence). JAMA 1993; 270: 83-90.

2. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.

3. Weiss P, Zvěřina J. Sexuální chování v ČR - situace a trendy. Praha: Portál 2001; 159.

4. Virag R. Intracavernous injection of papaverine for erectile dysfunction. Letter to the editor. Lancet 1982; 2: 938.

5. Michal V, Pospíchal J. Phalloarteriography in the diagnosis of erectile impotence. World J Surg 1978; 2(2): 239-248.

6. Ishii Watanabe H, Irisawa C et al. Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin E1 for organic impotence. Nippon Hinyokika Gakkai Kasshi 1986; 77: 954-962.

7. Breza J. Erektilné poruchy. Martin: Osveta 1994.

8. Verner P, Zvěřina J, Kočí K. Intrakavernózní aplikace papaverinu a fentolaminu u pacientů s poruchami erekce. Prakt Lek 1988; 68: 807-810.

9. Goldstein I, Borges FD, Fitch WP et al. Rescuing the failed papaverine/phentolamine erection: a proposed synergistic action of papaverine, phentolamine and prostaglandin E1 J Urol 1990; 143: 304A (Abstrakt). 10. Montorsi F, Salonia A, Deho' F et al. Pharma­co­lo­gi­cal management of erectile dysfunction. BJU Int 2003; 91: 446-454.

11. Moreland RB, Traish A, McMillin MA et al. PGE1 suppresses the induction of new collagen synthesis by transforming growth factor beta-1 in human corpus cavernosum smooth muscle: mechanism of penile ischemia associated fibrosis. J Urol 1994; 151: 431A (Abstrakt).

12. Barada JH, McKimmy RM. Vasoactive pharmacotherapy. Philadelphia: WB Saunders 1994: 229-250.

13. Porst H, Buvat J, Meuleman E et al. Intracaver­nous Alprostadil Alfadex - an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998; 10(4): 225-231.

14. Shabsigh R, Padma-Nathan H, Gittleman M et al. Intracavernous alprostadil Alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 477-480.

15. Heráček J, Lukeš M, Kuncová J et al. Intrakaver­nózní aplikace prostaglandinu E1 v léčbě erektilní dysfunkce po radikální prostatektomii. Čes Urol 2002; 2: 6 (Abstrakt).

16. Purvis K, Egdetveit I, Christiansen E. Intra­caver­nosal therapy for erectile failure - impact of treatment and reasons for drop-out and dissatisfaction. Int J Impot Res 1999; 295: 287-299.

Labels
Paediatric urologist Urology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account